OptimizeRx publishes corporate presentation on AI-driven healthcare marketing platform DAAP

OptimizeRx Corporation

OptimizeRx Corporation

OPRX

0.00
  • OptimizeRx outlined fiscal 2026 guidance for revenue of USD 95 million to USD 100 million, adjusted EBITDA of USD 21 million to USD 25 million.
  • Reported Q1 2026 revenue of USD 19.8 million, adjusted EBITDA of USD 3.3 million, GAAP net income of USD -0.5 million.
  • Highlighted a trailing-12-month net revenue retention rate of 110%, down from 114% a year earlier.
  • Disclosed USD 20.2 million of cash and cash equivalents, USD 23.6 million of total debt as of March 31, 2026.
  • Listed shares outstanding of about 18,800,000, market capitalization of about USD 97.2 million, stock price of USD 5.18.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.